Plain-language summary

This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years to 75 Years years
• Newly diagnosed, not yet treated
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Ifupinostat Hydrochloride for Injection (DRUG): Administered by intravenous infusion at a dose of 8.2 mg/m² or 18.5 mg/m². It is administered on days 1, 3, 5, 8, 10, and 12 of each cycle. Each cycle lasts 21 days. | Cyclophosphamide for Injection (DRUG): Administered by intravenous infusion at a dose of 750 mg/m². It is administered on day 1 of each cycle. Each cycle lasts 21 days. | Doxorubicin Hydrochloride for Injection (DRUG): Administered by intravenous infusion at a dose of 50 mg/m². It is administered on day 1 of each cycle. Each cycle lasts 21 days. | Vincristine Sulfate for Injection (DRUG): Administered by intravenous infusion at a dose of 1.4 mg/m² (maximum dose of 2 mg). It is administered on day 1 of each cycle. Each cycle lasts 21 days. | Prednisone Acetate Tablets (DRUG): Administered by mouth at a dose of 100 mg. It is administered on days 1 through 5 of each cycle. Each cycle lasts 21 days.

Drugs / treatments

Ifupinostat Hydrochloride for Injection, Cyclophosphamide for Injection, Doxorubicin Hydrochloride for Injection, Vincristine Sulfate for Injection, Prednisone Acetate Tablets

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details